Analysis on the Rationality of Aspirin in Inpatients with Diabetes
CHEN Zhe1, JI Li-wei2, XIE Xiao-hui1*
1. School of Pharmaceutical Sciences, Peking University, Beijing 100191, China; 2. Department of Pharmacy, Beijing Hospital National Medical Center, Beijing 100730, China
Abstract��OBJECTIVE To investigate the use of aspirin in patients hospitalized in department of endocrinology from October 1st, 2015 to March 31th, 2016 and analyze the rationality use of aspirin to promote the proper use. METHODS The appropriateness of aspirin use was analyzed according to relevant guidelines, literature etc. And the safety was analyzed through observing the incidence of adverse drug reaction(ADR). RESULTS The 204 patients were included. For patients with cardiovascular disease or with high cardiovascular risk, aspirin should be used according to guidelines. But the actual utilization rate of aspirin was 62.50% in these two kinds of patients. About 23% of patients used aspirin after a meal which should be used on an empty stomach based on instruction. Although these patients used some drugs that could interact with aspirin, no adverse events observed during hospitalization. For inpatients who used aspirin, the proportion of ADR was only 1.83%. CONCLUSION Rational use of aspirin need to be further improved, the safety of 100 mg aspirin is good.
����, ����ΰ, л����. סԺ�����߰�˾ƥ��ʹ�ú���������[J]. �й�ҩѧ��־, 2018, 53(3): 234-238.
CHEN Zhe, JI Li-wei, XIE Xiao-hui. Analysis on the Rationality of Aspirin in Inpatients with Diabetes. Chinese Pharmaceutical Journal, 2018, 53(3): 234-238.
TANG X M. The application of aspirin in cardiovascular disease [J]. Chin J Mod Drug App(�й��ִ�ҩ��Ӧ��),2010,4(5):119-120.
[2]
ZHOU Y, BAO M L, HUANG S Q, et al. Analysis on aspirin use in patients with diabetes mellitus [J]. Guide China Med (�й�ҽҩָ��),2012,10(16):176-177.
[3]
WANG Y M, XIE W Z. Clinical application of aspirin in diabetes prevention [J]. Prog Pharm Sci(ҩѧ��չ),2007,31(11):520-521.
[4]
WANG X R, PEI Y, LI Q M, et al. Utilization of aspirin in patients with type 2 diabetes mellitus [J]. J China Pharm(�й�ҩ��), 2008,19(23):1774-1775.
[5]
PENG W X, CHEN J H, MEI D, et al. Brief analysis of aspirin resistance and its implications [J]. Chin Pharm J(�й�ҩѧ��־),2017,52(14):1285-1290.
[6]
TANTRY U S, BLIDEN K P, GURBEL P A. Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation [J]. J Am Coll Cardiol,2005,46(9):1705-1709.
[7]
CHEN W H, CHENG X, LEE P Y, et al. Aspirin resistance and adverse clinical events in patients with coronary artery disease[J]. Am J Med,2007,120(7):631-635.
[8]
Chinese Diabetes Society. China guideline for type 2 diabetes(2013 edition) [J]. Chin J Diabete(�л�������־),2014,6(7):447-498.
[9]
American Diabetes Association. Standards of medical care in diabetes��2016 abridged for primary care providers[J]. Clin Diabetes,2016,34(1):3-21.
[10]
LUO W Y, TANG F M, WU J, et al. A survey on administration of aspirin for diabetic patients in a community hospital [J]. J Pract Med(ʵ��ҽѧ��־),2008,24(1):126-129.
[11]
GOFF D C, LLOYD-JONES D M, BENNETT G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines[J]. J Am Coll Cardiol, 2014, 63(25 Pt B): 2935-2959.
[12]
JI L W, XIE J, CAI Q, et al. Analysis of drug-drug interactions in prescriptions for hospitalized diabetic patients [J]. Chin Pharm J(�й�ҩѧ��־), 2014,49(11):944-947.
[13]
GU Z, WANG J. Interactions between aspirin and other medicines [J]. Chin Hosp Pharm J(�й�ҽԺҩѧ��־),1996,16(10):455-457.
[14]
LIU X Y. Analysis of aspirin withdrawal factors in patients with cardiovascular and cerebrovascular disease [J]. World Latest Med Inf(��������ҽѧ��Ϣ��ժ),2015,15(7):109-110.
[15]
WANG Z F, FENG R J, LI B, et al. Meta-analysis of aspirin in primary prevention of cardiovascular events in patients with diabetes[J]. J Qinghai Med Coll(�ຣҽѧԺѧ��),2015,36(1):59-64.
[16]
PATRONO C, GARCIA RODRIGUEZ L A, LANDOLFI R, et al. Low-dose aspirin for the prevention of atherothrombosis[J]. N Engl J Med, 2005,353:2373-2383.
[17]
HERNANDEZ-DIAZ S, GARCIA RODRIGUEZ L A. Cardioprotective aspirin users and their excess risk of upper gastrointestinal complications[J]. BMC Med, 2006,4:22.
[18]
GERSTEIN N S, SCHULMAN P M, GERSTEIN W H, et al. Should more patients continue aspirin therapy perioperatively?[J]. Ann Surg,2012,255(5):811-819.
[19]
XIONG L, HE G Q, HOSPIEAL J C. The study of tooth extractions for patients taking aspirin for a long-term [J]. J Clin Stomatol(�ٴ���ǻҽѧ��־),2014, 30(7):419-420.
[20]
LU M M, GAO Y M. Clinical effects of small doses of aspirin on socket bleeding in residual root extraction [J]. J Oral Maxillofacial Surgery(��ǻ��������־),2013,23(1):42-45.
[21]
LIU C A, YUAN M B. The study of gastrointestinal mucosal injury caused by aspirin [J]. Chin J Intern Med(�л��ڿ���־),1998,37(8):564-565.
[22]
LIAN X F, XIANG D C. The effect on gastrointestinal side effects of enteric aspirin��s taking time [J]. Chin J Coal Ind Med(�й�ú̿��ҵҽѧ��־),2005,8(5):457-458.
[23]
MCALL N T, TOILER G H, SCHAFER A I, et al. Collaborative Meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients[J]. BMJ,2002(324):71-86.
[24]
LU C L, GAO L L, SUN T, et al. The effect on TXA2 and PGI2 of low-dose aspirin��s different taking time[J]. Chin J Geriatr Heart Brain Vessel Dis(�л���������Ѫ�ܲ���־),2003,5(4):267.
[25]
WANG W, CHEN Y L, HOU X L, et al. Study on the influence of different aspirin��s taking time on patients with carotid plaque [J]. Chin Primary Health Care(�������������),2015,29(9):104-105.
2018, Vol. 53 
